Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression
about
The regulation of TGF-β/SMAD signaling by protein deubiquitination.A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancerCritical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transitionPrediagnostic circulating anti-Müllerian hormone concentrations are not associated with prostate cancer riskRisk for ESRD in type 1 diabetes remains high despite renoprotection.The PCa Tumor Microenvironment.The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of integrin-β8 in prostate cancer cells.Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.Network analysis of an in vitro model of androgen-resistance in prostate cancer.Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model.APPL proteins promote TGFβ-induced nuclear transport of the TGFβ type I receptor intracellular domain.Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesisThe Endocrine Society Centennial: Hormones and Apoptosis in the Prostate Gland… Live and Let DieTGF-β1 regulates the invasive and metastatic potential of mucoepidermoid carcinoma cellsProstate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.Soy isoflavones and prostate cancer: a review of molecular mechanisms.TGF-beta signalling and immunity in prostate tumourigenesis.A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands.The reactive stroma microenvironment and prostate cancer progression.Autophagy in prostate cancer and androgen suppression therapy.Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.Expression of TGFβ3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement of PI3-kinase/AKT signaling pathway.Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage.Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis.Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.A new therapy paradigm for prostate cancer founded on clinical observations.CCT6A suppresses SMAD2 and promotes prometastatic TGF-β signaling.The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy developmentMED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.NUSAP1 promotes invasion and metastasis of prostate cancerTGF-β signal rewiring sustains epithelial-mesenchymal transition of circulating tumor cells in prostate cancer xenograft hosts.Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells.Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells.Differential role of PTEN in transforming growth factor β (TGF-β) effects on proliferation and migration in prostate cancer cells.Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.Profiling Prostate Cancer Therapeutic Resistance.Mechanisms navigating the TGF-β pathway in prostate cancer.Apigenin inhibits TGF-β-induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism.Fatty Acids and Calcium Regulation in Prostate Cancer.Correlation between DEC1/DEC2 and epithelial‑mesenchymal transition in human prostate cancer PC‑3 cells
P2860
Q33857612-C1C800D8-A85B-4B2B-AD70-361D28B4C791Q34125720-5F9161AE-7512-4346-B5FC-FF2926E11CD0Q34243311-AB01B7CC-689E-469B-9CA9-6C32FB524DCFQ34458280-B111CDCB-8AB4-4EB8-80B3-ADFD20F1CB49Q34695426-84C21EAE-00B8-41C6-91CF-FCCCACC654D5Q35603143-05E8B3A3-04DF-4908-AB6D-816929869ECBQ35606620-EAE3F9CC-BF70-472E-85CE-FA07303E1F76Q35618835-DAF3373D-B951-4FCA-8912-385030A9CD71Q35836735-DC7E2E66-DFB1-43B5-A0C1-C0C9B45E00F2Q36147503-F5EED00C-5936-45FA-91CD-DA1ED90558D2Q36729386-659E9B48-3B91-4378-93B4-D6B3C9CC0C57Q36827512-26A18D7C-9BD8-4D7A-B54A-42B6061D9F89Q36965253-3698A168-2B89-4C45-A59A-1C519E1CE6F2Q37044664-ADFE7B89-8E55-4E4F-AAD9-2B7584050609Q37537958-F613A535-DD11-405D-ABC3-D10FF8C197F8Q37654590-6D10377E-D609-4454-AAFA-E9DF2342A40FQ37670250-EC83D094-D0D9-4B62-A4E5-7E211502D209Q37699186-4958F0C3-2D60-42E5-B917-F4A88795C917Q38038833-DCE2FE44-9D32-4B31-A498-EA598323B3BCQ38112596-8419C287-9B5D-457E-BD82-F1F1E47188E0Q38136271-41537358-9CC5-4C42-BD78-2F2B5970872EQ39335055-03B658AE-2B69-4199-BCCE-348F32FFD6F8Q39566584-DC812FE8-EF4B-4736-ACCB-02DC31FBECBAQ39595827-C7FBAEDA-6A4F-4488-B746-55FE7645A45FQ39705442-5D0A4CB1-C9E9-44C6-BE7F-9A9CBECF6C9CQ41871408-39CD9E97-7423-4F42-BC11-BC6D6E375255Q41915296-136AE9E1-BEF2-457B-B438-905CFC737947Q41915850-6D21A7ED-D3C6-48FD-B6D4-F69A2467D060Q42022308-67A3CF6D-E7EB-4A4F-BC55-36CDD52A57BDQ42244850-C8B30A3C-BD2F-4D95-81F4-C6851C7CC799Q42314595-FA6A63F0-A142-46EC-B92A-A673DB78FE2AQ43117942-2D5BAFAD-C01E-4159-A92F-51D9D786385CQ47435335-69B192AC-E50E-416D-B1F2-650CE7B08408Q48229042-885EBAA4-BD13-4853-9016-B6D713DFE28EQ48834589-CDCB3FD9-51B7-41F3-B64D-376A72B4871BQ52644478-09B1AE4F-9592-460C-8DC5-5F8CCC25960FQ54299380-63DE2931-3D6D-4FCA-B13A-910BC22736D6Q54453412-4C598462-1753-4693-966C-DE442EA9CE52Q55468609-AAF8467F-F153-43A3-B0D2-3800B70475FEQ58792238-586743F8-9284-498B-A9D1-27E42D55A240
P2860
Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression
description
im Februar 2009 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2009
@uk
name
Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression
@en
Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression
@nl
type
label
Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression
@en
Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression
@nl
prefLabel
Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression
@en
Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression
@nl
P2093
P2860
P1476
Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression
@en
P2093
Elisabeth Jones
Natasha Kyprianou
P2860
P304
P356
10.1517/14728220802705696
P407
P577
2009-02-01T00:00:00Z